Traditional Therapies for Severe Asthma

Immunol Allergy Clin North Am. 2016 Aug;36(3):581-608. doi: 10.1016/j.iac.2016.03.013.

Abstract

Severe asthma is a complex and heterogeneous disease. The European Respiratory Society and American Thoracic Society guidelines define severe asthma for patients 6 years or older as "asthma which requires treatment with high-dose inhaled corticosteroids…plus a second controller or systemic corticosteroids to prevent it from becoming 'uncontrolled' or which remains 'uncontrolled' despite this therapy." This article reviews available traditional therapies, data behind their uses in severe asthma, and varying recommendations. As various asthma endotypes and phenotypes are better understood and characterized, targeted therapies should help improve disease outcomes, efficacy, and cost-effectiveness.

Keywords: Add-on therapies; Controller therapies; European Respiratory Society and American Thoracic Society (ERS/ATS); Expert Panel Report 3 (EPR-3); Global Initiative for Asthma (GINA); Guidelines; Nonbiologic therapies; Severe asthma.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage
  • Adrenal Cortex Hormones / adverse effects
  • Adrenal Cortex Hormones / therapeutic use
  • Adrenergic beta-Agonists / administration & dosage
  • Adrenergic beta-Agonists / adverse effects
  • Adrenergic beta-Agonists / therapeutic use
  • Age Factors
  • Anti-Asthmatic Agents / administration & dosage
  • Anti-Asthmatic Agents / adverse effects
  • Anti-Asthmatic Agents / therapeutic use
  • Asthma / diagnosis
  • Asthma / immunology
  • Asthma / therapy*
  • Combined Modality Therapy
  • Desensitization, Immunologic
  • Disease Management
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Muscarinic Antagonists / administration & dosage
  • Muscarinic Antagonists / adverse effects
  • Muscarinic Antagonists / therapeutic use
  • Omalizumab / administration & dosage
  • Omalizumab / adverse effects
  • Omalizumab / therapeutic use
  • Practice Guidelines as Topic
  • Pregnancy
  • Severity of Illness Index

Substances

  • Adrenal Cortex Hormones
  • Adrenergic beta-Agonists
  • Anti-Asthmatic Agents
  • Muscarinic Antagonists
  • Omalizumab